Patient characteristics, stratified by total EM in the GVH and HVG directions
| Patient characteristic . | Total, N = 148 . | Total GVH EM below the median, N = 76 . | Total GVH EM above the median, N = 72 . | P* . | Total HVG EM below the median, N = 72 . | Total HVG EM above the median, N = 76 . | P* . |
|---|---|---|---|---|---|---|---|
| Male sex, n (%) | 75 (50.7) | 36 (47.4) | 39 (54.2) | NS | 36 (50.0) | 39 (51.3) | NS |
| Male sex, donor, n (%) | 92 (62.2) | 50 (65.8) | 42 (58.3) | NS | 45 (62.5) | 47 (61.8) | NS |
| Age at transplant, median (range), y | 53 (19-73) | 53 (19-73) | 50 (21-72) | NS | 52 (19-73) | 53 (19-73) | NS |
| Donor age at transplant, median (range), y | 42 (15-70) | 43 (15-70) | 42 (15-67) | NS | 43 (15-69) | 42 (16-70) | NS |
| Patient ethnicity, n (%) | |||||||
| African American | 23 (15.5) | 15 (19.7) | 8 (11.1) | NS | 14 (19.4) | 9 (11.8) | NS |
| White | 119 (80.4) | 57 (75.0) | 62 (86.1) | 55 (76.4) | 63 (84.2) | ||
| Other | 6 (4.1) | 4 (5.3) | 2 (2.8) | 3 (4.2) | 3 (4.0) | ||
| Sex mismatch, n (%) | |||||||
| Female patient/donor | 29 (19.6) | 13 (17.1) | 16 (22.2) | NS | 16 (22.2) | 13 (17.1) | NS |
| Female patient, male donor | 44 (29.7) | 27 (35.5) | 17 (23.6) | 20 (27.8) | 24 (31.6) | ||
| Male patient, female donor | 27 (18.2) | 13 (17.1) | 14 (19.4) | 11 (15.3) | 16 (21.1) | ||
| Male patient/donor | 48 (32.4) | 23 (30.3) | 25 (34.7) | 25 (34.7) | 23 (30.1) | ||
| Donor relationship, n (%) | |||||||
| Child | 51 (34.9) | 26 (34.7) | 25 (35.2) | 24 (33.8) | 27 (36.0) | ||
| Parent | 23 (15.8) | 13 (17.3) | 10 (14.1) | 8 (11.3) | 15 (20.0) | ||
| Sibling | 72 (49.3) | 36 (48.0) | 36 (50.7) | 39 (54.9) | 33 (44.0) | ||
| Other | 2 (1.4) | ||||||
| CMV serostatus, n (%) | |||||||
| Donor/recipient positive | 45 (30.4) | 21 (27.6) | 24 (33.3) | NS | 27 (37.5) | 18 (23.7) | .088 |
| Donor positive, recipient negative | 19 (12.8) | 8 (10.5) | 11 (15.3) | 5 (6.9) | 14 (18.4) | ||
| Donor negative, recipient positive | 39 (26.4) | 23 (20.3) | 16 (22.2) | 20 (27.8) | 19 (25.0) | ||
| Donor/recipient negative | 45 (30.4) | 24 (31.6) | 21 (29.2) | 20 (27.8) | 25 (32.9) | ||
| ABO mismatch, n (%) | |||||||
| Bidirectional | 5 (3.4) | 3 (4.0) | 2 (2.8) | NS | 1 (1.4) | 4 (5.3) | NS |
| Major | 21 (14.2) | 10 (13.2) | 11 (15.3) | 10 (13.9) | 11 (14.5) | ||
| Minor | 28 (18.9) | 15 (19.7) | 13 (18.1) | 11 (15.3) | 17 (22.4) | ||
| Matched | 94 (63.5) | 48 (63.2) | 46 (63.9) | 50 (69.4) | 44 (57.9) | ||
| KPS, median (range) | 80 (50-100) | 85 (50-100) | 80 (50-100) | NS | 90 (50-100) | 80 (50-100) | .050 |
| HCT-CI,38 median (range) | 3 (0-9) | 3 (0-9) | 3 (0-9) | NS | 3.5 (0-9) | 3 (0-9) | NS |
| CD34 cell dose, median (range), 106 cells/kg | 5 (1.6-14.2) | 5 (2.4-14.2) | 5 (1.6-9.3) | NS | 5.0 (2.4-9.3) | 5.0 (1.6-14.2) | NS |
| CD3 cell dose, median (range), 107 cells/kg | 17.8 (0-68.5) | 17.3 (0.1-68.5) | 19.3 (0-59.4) | NS | 18.1 (0.1-59.4) | 17.4 (0-68.5) | NS |
| Ablative regiment received, n (%) | 61 (41.2) | 25 (32.9) | 36 (50.0) | .035 | 26 (36.1) | 35 (46.1) | NS |
| Diagnosis, n (%) | |||||||
| AML | 95 (64.2) | 46 (60.5) | 49 (68.1) | NS | 47 (65.3) | 48 (63.2) | NS |
| Other (ALL, MDS, severe aplastic anemia, lymphoma, multiple myeloma, other leukemia) | 53 (35.8) | 30 (39.5) | 23 (31.9) | 25 (34.7) | 28 (36.8) | ||
| Active disease at transplant, n (%) | 60 (40.5) | 26 (36.6) | 34 (48.6) | .15 | 25 (36.8) | 35 (48.0) | .18 |
| DRI,37 n (%) | |||||||
| Low/intermediate | 64 (45.4) | 33 (46.5) | 31 (44.3) | NS | 34 (50.0) | 30 (41.1) | NS |
| High/very high | 77 (54.6) | 38 (53.5) | 39 (55.7) | 34 (50.0) | 43 (58.9) | ||
| N/A (aplastic anemia) | 7 (4.7) | ||||||
| Presence of DSAs, n (%) | 23 (15.8) | 10 (13.2) | 13 (18.1) | NS | 8 (11.1) | 15 (19.7) | NS |
| Not tested | 22 (14.9) | 10 (13.2) | 12 (16.7) | 11 (15.3) | 11 (14.5) | ||
| Recipient anti-HLA antibodies, n (%) | |||||||
| Class I | 61 (41.2) | 29 (43.9) | 32 (53.3) | NS | 30 (49.2) | 31 (47.7) | NS |
| Class II | 34 (27.0) | 16 (24.2) | 18 (30.0) | NS | 15 (24.6) | 19 (23.2) | NS |
| Class I and II | 64 (50.8) | 30 (45.4) | 34 (56.7) | NS | 31 (50.8) | 33 (50.8) | NS |
| Not tested | 22 (14.9) | ||||||
| History of prior allo-HCT, n (%) | 44 (29.7) | 18 (23.7) | 26 (36.1) | .098 | 17 (23.6) | 27 (35.5) | .11 |
| Patient characteristic . | Total, N = 148 . | Total GVH EM below the median, N = 76 . | Total GVH EM above the median, N = 72 . | P* . | Total HVG EM below the median, N = 72 . | Total HVG EM above the median, N = 76 . | P* . |
|---|---|---|---|---|---|---|---|
| Male sex, n (%) | 75 (50.7) | 36 (47.4) | 39 (54.2) | NS | 36 (50.0) | 39 (51.3) | NS |
| Male sex, donor, n (%) | 92 (62.2) | 50 (65.8) | 42 (58.3) | NS | 45 (62.5) | 47 (61.8) | NS |
| Age at transplant, median (range), y | 53 (19-73) | 53 (19-73) | 50 (21-72) | NS | 52 (19-73) | 53 (19-73) | NS |
| Donor age at transplant, median (range), y | 42 (15-70) | 43 (15-70) | 42 (15-67) | NS | 43 (15-69) | 42 (16-70) | NS |
| Patient ethnicity, n (%) | |||||||
| African American | 23 (15.5) | 15 (19.7) | 8 (11.1) | NS | 14 (19.4) | 9 (11.8) | NS |
| White | 119 (80.4) | 57 (75.0) | 62 (86.1) | 55 (76.4) | 63 (84.2) | ||
| Other | 6 (4.1) | 4 (5.3) | 2 (2.8) | 3 (4.2) | 3 (4.0) | ||
| Sex mismatch, n (%) | |||||||
| Female patient/donor | 29 (19.6) | 13 (17.1) | 16 (22.2) | NS | 16 (22.2) | 13 (17.1) | NS |
| Female patient, male donor | 44 (29.7) | 27 (35.5) | 17 (23.6) | 20 (27.8) | 24 (31.6) | ||
| Male patient, female donor | 27 (18.2) | 13 (17.1) | 14 (19.4) | 11 (15.3) | 16 (21.1) | ||
| Male patient/donor | 48 (32.4) | 23 (30.3) | 25 (34.7) | 25 (34.7) | 23 (30.1) | ||
| Donor relationship, n (%) | |||||||
| Child | 51 (34.9) | 26 (34.7) | 25 (35.2) | 24 (33.8) | 27 (36.0) | ||
| Parent | 23 (15.8) | 13 (17.3) | 10 (14.1) | 8 (11.3) | 15 (20.0) | ||
| Sibling | 72 (49.3) | 36 (48.0) | 36 (50.7) | 39 (54.9) | 33 (44.0) | ||
| Other | 2 (1.4) | ||||||
| CMV serostatus, n (%) | |||||||
| Donor/recipient positive | 45 (30.4) | 21 (27.6) | 24 (33.3) | NS | 27 (37.5) | 18 (23.7) | .088 |
| Donor positive, recipient negative | 19 (12.8) | 8 (10.5) | 11 (15.3) | 5 (6.9) | 14 (18.4) | ||
| Donor negative, recipient positive | 39 (26.4) | 23 (20.3) | 16 (22.2) | 20 (27.8) | 19 (25.0) | ||
| Donor/recipient negative | 45 (30.4) | 24 (31.6) | 21 (29.2) | 20 (27.8) | 25 (32.9) | ||
| ABO mismatch, n (%) | |||||||
| Bidirectional | 5 (3.4) | 3 (4.0) | 2 (2.8) | NS | 1 (1.4) | 4 (5.3) | NS |
| Major | 21 (14.2) | 10 (13.2) | 11 (15.3) | 10 (13.9) | 11 (14.5) | ||
| Minor | 28 (18.9) | 15 (19.7) | 13 (18.1) | 11 (15.3) | 17 (22.4) | ||
| Matched | 94 (63.5) | 48 (63.2) | 46 (63.9) | 50 (69.4) | 44 (57.9) | ||
| KPS, median (range) | 80 (50-100) | 85 (50-100) | 80 (50-100) | NS | 90 (50-100) | 80 (50-100) | .050 |
| HCT-CI,38 median (range) | 3 (0-9) | 3 (0-9) | 3 (0-9) | NS | 3.5 (0-9) | 3 (0-9) | NS |
| CD34 cell dose, median (range), 106 cells/kg | 5 (1.6-14.2) | 5 (2.4-14.2) | 5 (1.6-9.3) | NS | 5.0 (2.4-9.3) | 5.0 (1.6-14.2) | NS |
| CD3 cell dose, median (range), 107 cells/kg | 17.8 (0-68.5) | 17.3 (0.1-68.5) | 19.3 (0-59.4) | NS | 18.1 (0.1-59.4) | 17.4 (0-68.5) | NS |
| Ablative regiment received, n (%) | 61 (41.2) | 25 (32.9) | 36 (50.0) | .035 | 26 (36.1) | 35 (46.1) | NS |
| Diagnosis, n (%) | |||||||
| AML | 95 (64.2) | 46 (60.5) | 49 (68.1) | NS | 47 (65.3) | 48 (63.2) | NS |
| Other (ALL, MDS, severe aplastic anemia, lymphoma, multiple myeloma, other leukemia) | 53 (35.8) | 30 (39.5) | 23 (31.9) | 25 (34.7) | 28 (36.8) | ||
| Active disease at transplant, n (%) | 60 (40.5) | 26 (36.6) | 34 (48.6) | .15 | 25 (36.8) | 35 (48.0) | .18 |
| DRI,37 n (%) | |||||||
| Low/intermediate | 64 (45.4) | 33 (46.5) | 31 (44.3) | NS | 34 (50.0) | 30 (41.1) | NS |
| High/very high | 77 (54.6) | 38 (53.5) | 39 (55.7) | 34 (50.0) | 43 (58.9) | ||
| N/A (aplastic anemia) | 7 (4.7) | ||||||
| Presence of DSAs, n (%) | 23 (15.8) | 10 (13.2) | 13 (18.1) | NS | 8 (11.1) | 15 (19.7) | NS |
| Not tested | 22 (14.9) | 10 (13.2) | 12 (16.7) | 11 (15.3) | 11 (14.5) | ||
| Recipient anti-HLA antibodies, n (%) | |||||||
| Class I | 61 (41.2) | 29 (43.9) | 32 (53.3) | NS | 30 (49.2) | 31 (47.7) | NS |
| Class II | 34 (27.0) | 16 (24.2) | 18 (30.0) | NS | 15 (24.6) | 19 (23.2) | NS |
| Class I and II | 64 (50.8) | 30 (45.4) | 34 (56.7) | NS | 31 (50.8) | 33 (50.8) | NS |
| Not tested | 22 (14.9) | ||||||
| History of prior allo-HCT, n (%) | 44 (29.7) | 18 (23.7) | 26 (36.1) | .098 | 17 (23.6) | 27 (35.5) | .11 |
MDS, myelodysplastic syndrome; N/A, not applicable; NS, nonsignificant (P > .2).
The parametric P value is calculated by analysis of variance for numerical covariates and the χ2 test for categorical covariates.